Jan. 7 at 5:43 PM
EUDA Health Holdings Limited (NASDAQ:
$EUDA), a New and Notable company in the B2i Digital network, continues to execute its non-invasive healthcare strategy across Singapore, Malaysia, and China with recent developments demonstrating tangible progress across EUDA’s four business pillars. The company will launch EUDA Helixé 2.0 in January 2026, an enhanced formulation of its flagship nutraceutical with improved bioavailability and halal certification designed to support broader market access. This follows management’s projection of up to 500,000 bottles in annual sales for the product line.
In December 2025, EUDA announced the establishment of a nationwide stem cell extraction, cryogenic storage, and clinical delivery platform in China through partnerships with Shenzhen Inno Immune Co., Ltd. and Wuhan Kaien Hospital. This infrastructure enables centralized processing and quality control while expanding geographic reach through a growing network of partner institutions across China.
The company’s Bioenergy Capsule wellness system continues its regional rollout through subsidiaries and partners in Singapore (EHPL), Malaysia (CK Health), and China (Keylock), progressing toward its target of more than 1,000 units deployed across Southeast Asia.
EUDA has also expanded its regenerative medicine portfolio through distribution agreements providing access to T-cell immunotherapy at approximately USD 8,000 per treatment, according to company disclosures, and maintains partnerships with 37 treatment centers across China, Indonesia, and Cambodia.
These operational milestones position EUDA within Asia’s growing preventive healthcare market, where aging demographics are driving demand for longevity-focused solutions. To learn more about EUDA Health Holdings Limited, visit https://www.eudahealth.com.
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
